Research

The Yale Center for Asthma and Airways Diseases (YCAAD) is a highly regarded academic clinical center recognized for its excellence in education, research, and patient care. The center consists of three programs: the Asthma Program, the Bronchiectasis and Nontuberculous Mycobacteria (NTM) Infections Program, and the Chronic Obstructive Pulmonary Disease (COPD) Program.

Established in 2000, YCAAD provides opportunities for patients with complicated airway diseases to participate in innovative research through industry-sponsored clinical trials and NIH-funded translational research. In addition to advancing cutting-edge research to improve patients’ lives, YCAAD is committed to training the next generation of leaders in the field. The center provides education opportunities for students, residents, fellows, and health care providers around the region on the cutting-edge management of airway diseases.

Publications

2026

Twice-yearly Depemokimab (Depe) Reduces Exacerbations and Improves Quality of Life (QoL) in Patients (Pts) With Uncontrolled Asthma Symptoms at Baseline (BL): Subgroup Analyses of the Phase III SWIFT-1/2 Studies
Skowasch D, Pavord I, Chupp G, Jackson D, Muccino D, Forth R, Kwiatek J, Vichiendilokkul A, Jackson D. Twice-yearly Depemokimab (Depe) Reduces Exacerbations and Improves Quality of Life (QoL) in Patients (Pts) With Uncontrolled Asthma Symptoms at Baseline (BL): Subgroup Analyses of the Phase III SWIFT-1/2 Studies. Pneumologie 2026, 80: s178-s179. DOI: 10.1055/s-0046-1816513.
Peer-Reviewed Original Research
PrecISE- A Biomarker Stratified Adaptive Trial of 5 Interventions in Severe Asthma: Final Protocol and the Baseline Cohort
Denlinger L, Israel E, Moore W, Georas S, Wright R, Castro M, Peden D, Anstrom K, Bleecker E, Alexander L, Cahill K, Cardet J, Carr T, Cedano J, Chen A, Chupp G, Comhair S, DiMango E, Erzurum S, Fahy J, Fajt M, Gaston B, Jackson D, Jain S, Jarjour N, Kenyon N, Kraft M, Krishnan J, Kumar R, Lugogo N, Martinez F, Marquis M, Pappalardo A, Phipatanakul W, Rank M, Rosenberg S, Salciccioli J, Sanchez M, Smith L, Sumino K, Szefler S, Tang M, Vijayanand P, Wechsler M, Wenzel S, White S, Zeki A, Ivanova A, Bacharier L, Akuthota P, Team N, Bleecker E, Carr T, Moore W, Rank M, Camacho G, Gerald L, Hastie A, Krings J, Martinez F, Merchen J, Meyers D, Nirendran N, Ortega V, Pippins A, Rusk A, Schunk R, Skeps R, Simmons T, Williamson P, Zein J, Israel E, Cardet J, DiMango E, Phipatanakul W, Bailey J, Banzon T, Bartnikas L, Baxi S, Betapudi V, Brick I, Casale T, Cinelli M, Crestani E, Cunningham A, Esty B, Fandozzi ;, Fernandez J, Fitzpatrick E, Flam B, Forth V, Gaffin J, Gentile K, Gueye-Ndiaye S, Haley K, Heromin R, Hauptmann M, Kaage T, Kelly M, Kraemer M, LaBere B, Lai P, Le M, Ledford D, Lee J, Lee J, Lockey R, Macginnitie A, McCarty K, Moss K, Mukharesh L, Pistenmaa A, Pepper A, Pimental M, Queheillalt D, Robinson A, Salciccioli J, Saroya T, Smith C, Trevedi M, Trippa L, Tulchinsky A, Vitiello A, Yee C, Zakar K, White T, Kumar R, Moy J, Rosenberg S, Aalemansour H, Buechler K, Carter T, Fu J, Hixon J, Jackson C, Ji Y, Johnson C, Kalhan R, Kane J, Kaur O, Li G, Lippner E, Makhija M, Maleckar S, Naureckas E, Nyenhuis S, Peters A, Press V, Qureshi M, Ryba D, Sheng J, Smith L, Xu B, Wechsler M, Szefler S, Chupp G, Holguin F, Kraft M, Liu A, Rogers L, Anderson D, Belimezova S, Bitzan J, Bose S, Brock J, Sanchez J, Clark B, Cohn L, Cotarian A, Cruse M, Eisenberg E, Estrom J, Glassmeyer I, Villalobos J, Grant N, Gruberg B, Guntur V, Hay O, Hills A, Hsieh J, Kessler J, Kolakowski C, Miyazawa N, Pak J, Pruitt D, Rhoads S, Sharma S, Stevens A, Tippin B, Valente C, Vicencio A, Wainscoat C, Weber J, Wessels G, White M, Winnica D, Zeitlin P, Denlinger L, Jarjour N, Krishnan J, Agnihotri N, Bach J, Bires N, DeLisa J, Fichtinger P, Floerke H, Fritz B, Grogan J, Guadarrama A, Hasse W, Jackson D, Kaspari R, Kelley R, Klaus D, Lowell P, Larson L, Norwick L, O’Brien M, Palas T, Pappalardo A, Read E, Schraml A, Schiebler M, Sorkness R, Tattersall M, Wollet L, Gaston B, Erzurum S, Teague W, Chmiel J, Ross K, Aronica M, Beck B, Bendy L, Borish L, Chedraoui C, Comhair S, Davis M, Dix A, Fakhry B, Gammell R, Gluvna A, Hamm E, Heskett M, Hu B, Khatri S, Kirwan J, Kloepfer K, Koo M, Labadia M, Marko A, Matheis N, Mey J, Mulya A, Murphy D, Owensby R, Parker L, Pennington E, Roesch E, Sharp J, Smith C, Solanki N, Veri L, Shifflett K, Yang F, Wenzel S, Lugogo N, Bagheri A, Cislo L, Fajt M, Gauthier M, Hadden M, James P, Mohan A, Moore J, Nouraie S, Ramonell R, Romanek R, Sullivan L, Trudeau J, Zhang M, Akuthota P, Jain S, Vijayanand P, Barry J, Beg N, Brickner H, Alexander L, Diaz D, Jafari Y, McKeon N, Fahy J, Kenyon N, Almario M, Charbit A, Cho L, Gale B, Haczku A, Harper R, Houston T, Kain C, Kivler C, Kuhn B, Liu M, McCourt P, Miller J, Nguyen A, Orain X, Peters M, Plough A, Ramirez K, Rossi L, Schivo M, Singapuri M, Teuber S, Tham T, Tompkins D, Vi J, Zeki A, Castro M, Bacharier L, Sumino K, Atha J, Boomer J, Cahill K, Clover A, Dorman V, Hoffman E, Jackson F, Klinck M, Krings J, Madison J, Quigley J, Quinones T, Saxena S, Sharpe M, Troyer J, Yen-Declue H, Zulich A, Ivanova A, Anstrom K, LaVange L, Bagaason S, Britt A, Bryan H, Burbank A, Chen A, Culpepper C, DeMarcus F, Fenu C, Gotman N, Green R, Harrison L, James J, Kosorok J, Kosorok M, Littleton L, Marquis M, O'Neal W, Peden D, Price R, Quibrera P, Ritz C, Sanchez M, Schwartz S, Slye N, Song T, Wilson N, Croxton T, Lu J, Noel P, Bamdad J, Georas S, Wright R. PrecISE- A Biomarker Stratified Adaptive Trial of 5 Interventions in Severe Asthma: Final Protocol and the Baseline Cohort. The Journal Of Allergy And Clinical Immunology 2026 PMID: 41707916, DOI: 10.1016/j.jaci.2026.02.001.
Peer-Reviewed Original Research
Concepts
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE).
Chupp G, Nagase H, Skowasch D, Devouassoux G, Côté A, Jackson D, Jackson D, Wechsler M, Imber V, McGinniss J, K S, Howarth P, Pavord I. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE). American Journal Of Respiratory And Critical Care Medicine 2026 PMID: 41738176, DOI: 10.1093/ajrccm/aamag031.
Peer-Reviewed Original Research
Concepts
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease
Zhang Y, Wei H, Nouws J, Jiang W, Brewster R, Nguyen J, Liang S, Pass S, Wang W, Collin F, Oill A, Kim S, Siller S, Liu J, Zhao A, Hansbro P, Dela Cruz C, Britto C, Gomez J, Cloonan S, Herzog E, Lam T, Banovich N, Raredon M, Zhang X, Mangiola S, Homer R, Kaminski N, McDonough J, Polverino F, Yan X, Sauler M. Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease. Nature Genetics 2026, 58: 376-391. PMID: 41578022, PMCID: PMC12900648, DOI: 10.1038/s41588-025-02480-z.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2025

Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma.
Kay S, Rajeevan H, Son M, Kwah J, Ramirez M, Liu Y, Wang Z, Yan X, Nino G, Britto C, Chupp G, Gomez J. Sex-biased Gene Expression Underlies Immune Dysfunction in Asthma. American Journal Of Respiratory Cell And Molecular Biology 2025, 73: 884-896. PMID: 40587876, DOI: 10.1165/rcmb.2024-0565oc.
Peer-Reviewed Original Research
Concepts
Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection.
Chorvinsky E, Bhattacharya S, Bera B, Welham A, Ismat K, Lawlor C, Preciado D, Gomez J, Morizono H, Pillai D, Gutierrez M, Jaiswal J, Nino G. Down Syndrome Alters Type III IFN and Proinflammatory Airway Epithelial Responses to Respiratory Syncytial Virus Infection. American Journal Of Respiratory Cell And Molecular Biology 2025, 73: 951-964. PMID: 40587878, PMCID: PMC12699336, DOI: 10.1165/rcmb.2025-0068oc.
Peer-Reviewed Original Research
Concepts
TEZEPELUMAB EFFICACY IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY EXACERBATION TRIGGERS IN NAVIGATOR AND DIRECTION
Lugogo N, Carr T, White A, Chupp G, Chase N, Lanz M, Marchese C, Lindsley A, Lal H, Ambrose C. TEZEPELUMAB EFFICACY IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY EXACERBATION TRIGGERS IN NAVIGATOR AND DIRECTION. Annals Of Allergy Asthma & Immunology 2025, 135: s47. DOI: 10.1016/j.anai.2025.08.150.
Peer-Reviewed Original Research
Concepts
SYSTEMATIC REVIEW ON THE PREVALENCE OF IMMUNOGLOBULIN G SUBCLASS DEFICIENCIES IN PATIENTS WITH ASTHMA.
Zidan E, Ahn J, Kang I, Chupp G, Shin J. SYSTEMATIC REVIEW ON THE PREVALENCE OF IMMUNOGLOBULIN G SUBCLASS DEFICIENCIES IN PATIENTS WITH ASTHMA. Annals Of Allergy Asthma & Immunology 2025, 135: s50. DOI: 10.1016/j.anai.2025.08.156.
Peer-Reviewed Original Research
Concepts
162 Sex-Specific monocyte interleukin signaling patterns in cystic fibrosis
Knight C, Yin H, Kizilirmak T, Adams T, Sauler M, Gomez J, Britto C. 162 Sex-Specific monocyte interleukin signaling patterns in cystic fibrosis. Journal Of Cystic Fibrosis 2025, 24: s95-s96. DOI: 10.1016/s1569-1993(25)01781-3.
Peer-Reviewed Original Research
EFFECT OF TEZEPELUMAB ON SYSTEMIC CORTICOSTEROID USE FOR EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD BY BLOOD EOSINOPHIL COUNT
CRINER G, CHUPP G, HAN M, SINGH D, MARCHESE C, MOLFINO N, MATSUNAGA Y, PONNARAMBIL S, AMBROSE C. EFFECT OF TEZEPELUMAB ON SYSTEMIC CORTICOSTEROID USE FOR EXACERBATIONS IN PATIENTS WITH MODERATE TO VERY SEVERE COPD BY BLOOD EOSINOPHIL COUNT. Chest 2025, 168: a7259-a7263. DOI: 10.1016/j.chest.2025.09.078.
Peer-Reviewed Original Research
Concepts
TWICE-YEARLY DEPEMOKIMAB REDUCES NEED FOR BURST ORAL CORTICOSTEROID USE IN PATIENTS WITH ASTHMA: POSTHOC ANALYSES OF THE PHASE III SWIFT-1/2 STUDIES
CHUPP G, BERNSTEIN D, JACQUES L, ZHU C, VICHIENDILOKKUL A, HOWARTH P, KWIATEK J, WECHSLER M, PAVORD I. TWICE-YEARLY DEPEMOKIMAB REDUCES NEED FOR BURST ORAL CORTICOSTEROID USE IN PATIENTS WITH ASTHMA: POSTHOC ANALYSES OF THE PHASE III SWIFT-1/2 STUDIES. Chest 2025, 168: a1-a3. DOI: 10.1016/j.chest.2025.07.007.
Peer-Reviewed Original Research
Concepts
Survey evaluating CompEx Asthma components, and current and future digital enablers
Chupp G, Hui C, Christenson S, Israel E, Janssens W, Kocks J, Siddiqui S, Haughney J, Topole E, Da Silva C, Bolton C. Survey evaluating CompEx Asthma components, and current and future digital enablers. 2025, pa1483. DOI: 10.1183/13993003.congress-2025.pa1483.
Peer-Reviewed Original Research
Work Practices and Respirable Crystalline Silica Exposures in Stone Countertop Fabrication Shops
McGowan C, Cantley L, Klein R, Redlich C. Work Practices and Respirable Crystalline Silica Exposures in Stone Countertop Fabrication Shops. American Journal Of Industrial Medicine 2025, 68: 973-987. PMID: 40946211, DOI: 10.1002/ajim.70020.
Peer-Reviewed Original Research
Concepts
Pediatric Airway Biology and Transcriptomic Assessment of Therapies
Nino G, Gomez J, Gutierrez M. Pediatric Airway Biology and Transcriptomic Assessment of Therapies. JAMA Pediatrics 2025, 179: 947-949. PMID: 40658411, DOI: 10.1001/jamapediatrics.2025.2070.
Peer-Reviewed Original Research
Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years
Canonica G, Bagnasco D, Lee J, Chupp G, Schleich F, Oppenheimer J, Zhang L, Alfonso-Cristancho R, Howarth P. Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years. ERJ Open Research 2025, 11: 01390-2024. PMID: 41220814, PMCID: PMC12598589, DOI: 10.1183/23120541.01390-2024.
Peer-Reviewed Original Research
Concepts
Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis
Chupp G, Heaney L, Pelaia G, Almonacid C, Maxwell A, Zhang L, Alfonso-Cristancho R, Howarth P, Brusselle G. Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 3286-3295. PMID: 40780384, DOI: 10.1016/j.jaip.2025.07.049.
Peer-Reviewed Original Research
Concepts
Military Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms
Hosseini R, Garshick E, Slade M, Timmons A, Korpak A, Smith N, Nakayama K, Baird C, Ciminera P, Kheradmand F, Fan V, Hart J, Koutrakis P, Kuschner W, Ioachimescu O, Jerrett M, Montgrain P, Proctor S, Wendt C, Wongtrakool C, Wan E, Blanc P, Redlich C. Military Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms. JAMA Network Open 2025, 8: e2522080. PMID: 40690216, PMCID: PMC12281241, DOI: 10.1001/jamanetworkopen.2025.22080.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation
Yu S, Hu B, Sun Y, Peng X, Lee C, Woo S, McGovern J, Zielonka J, Saber T, Ghincea A, Gandhi S, Walia A, Pivarnik T, Ishikawa G, Shao S, Sun H, Gunes B, Kujawski S, Perez S, Odell W, Hinchcliff M, Varga J, Feghali-Bostwick C, Sauler M, Gomez J, Ryu C, Herzog E. Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation. European Respiratory Journal 2025, 66: 2401564. PMID: 40374521, PMCID: PMC12332468, DOI: 10.1183/13993003.01564-2024.
Peer-Reviewed Original Research
Concepts
Hypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis
Adams T, Redlich C, Glazer C, Gulati M. Hypersensitivity pneumonitis associated with home mold exposure: A retrospective cohort analysis. PLOS ONE 2025, 20: e0323093. PMID: 40338891, PMCID: PMC12061107, DOI: 10.1371/journal.pone.0323093.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
The Potential Role of GPR87 in the Development of Pulmonary Fibrosis
Khoury J, Ahangari F, Justet A, Adams T, Manning E, Mcdonough J, Anderson S, Nekola F, Beermann M, Bauer Y, Gomez J, Kaminski N. The Potential Role of GPR87 in the Development of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7110-a7110. DOI: 10.1164/ajrccm.2025.211.abstracts.a7110.
Peer-Reviewed Original Research
Sex-Specific Immune Transcriptional Programming by Pseudomonas in Cystic Fibrosis
Knight C, Yin H, Kockar Kizilirmak T, Adams T, Sauler M, Gomez J, Britto-Leon C. Sex-Specific Immune Transcriptional Programming by Pseudomonas in Cystic Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1109-a1109. DOI: 10.1164/ajrccm.2025.211.abstracts.a1109.
Peer-Reviewed Original Research
High Exacerbators in Cystic Fibrosis Have Sex-Specific Neutrophil Transcriptomes
Knight C, Yin H, Kockar Kizilirmak T, Adams T, Sauler M, Gomez J, Britto-Leon C. High Exacerbators in Cystic Fibrosis Have Sex-Specific Neutrophil Transcriptomes. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a5557-a5557. DOI: 10.1164/ajrccm.2025.211.abstracts.a5557.
Peer-Reviewed Original Research
Barriers and Facilitators to Transitioning to Maintenance and Reliever Therapy for Patients With Moderate to Severe Asthma
Zaeh S, Hay O, Zimmerman Z, Chupp G, Eakin M. Barriers and Facilitators to Transitioning to Maintenance and Reliever Therapy for Patients With Moderate to Severe Asthma. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1473-a1473. DOI: 10.1164/ajrccm.2025.211.abstracts.a1473.
Peer-Reviewed Original Research
Concepts
Higher Acute Exposure to Air Pollution is Associated With Respiratory Hospitalizations in Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry
Sack C, Wojdyla D, Macmurdo M, Gassett A, Redlich C, Raghu G, Kaufman J, Olson A, Neely M, Snyder L, Gulati M. Higher Acute Exposure to Air Pollution is Associated With Respiratory Hospitalizations in Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a3245-a3245. DOI: 10.1164/ajrccm.2025.211.abstracts.a3245.
Peer-Reviewed Original Research
Concepts
Civilian Occupational Exposures and Current Respiratory Symptoms in Veterans Previously Deployed to Southwest Asia and Afghanistan
Mohazzab-Hosseinian S, Redlich C, Timmons A, Korpak A, Smith N, Nakayama K, Baird C, Ciminera P, Kheradmand F, Fan V, Hart J, Koutrakis P, Kuschner W, Ioachimescu O, Jerrett M, Montgrain P, Proctor S, Wendt C, Wongtrakool C, Wan E, Garshick E, Blanc P. Civilian Occupational Exposures and Current Respiratory Symptoms in Veterans Previously Deployed to Southwest Asia and Afghanistan. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a4259-a4259. DOI: 10.1164/ajrccm.2025.211.abstracts.a4259.
Peer-Reviewed Original Research
Concepts

See All Publications